Human Genome Epidemiology Literature Finder
|
Records 1 - 24 (of 24 Records) |
| Query Trace: Lung Neoplasms and CYP3A5[original query] |
|---|
| The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 2003 Oct 13 (10): 607-18. Dally Heike, Edler Lutz, Jäger Birgit, Schmezer Peter, Spiegelhalder Bertold, Dienemann Hendrik, Drings Peter, Schulz Volker, Kayser Klaus, Bartsch Helmut, Risch Ange |
| CYP3A5*1 is an inhibitory factor for lung cancer in Taiwanese. The Kaohsiung journal of medical sciences 2003 May 19 (5): 201-7. Yeh Kun-Tu, Chen Jui-Chang, Chen Chih-Mei, Wang Yu-Fen, Lee Tai-Ping, Chang Jan-Gow |
| Genotype relationships in the CYP3A locus in Caucasians. Cancer letters 2004 Apr 207 (1): 95-9. Dally Heike, Bartsch Helmut, Jäger Birgit, Edler Lutz, Schmezer Peter, Spiegelhalder Bertold, Dienemann Hendrik, Drings Peter, Kayser Klaus, Schulz Volker, Risch Ange |
| Significance of the minor cytochrome P450 3A isoforms. Clinical pharmacokinetics 2006 1 45 (1): 13-31. Daly Ann |
| CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer. Acta oncologica (Stockholm, Sweden) 2007 46 (3): 361-6. Pan Ji-Hong, Han Jin-Xiang, Wu Jian-Mei, Sheng Li-Jun, Huang Hai-N |
| Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Mar 26 (7): 1119-27. Rudin Charles M, Liu Wanqing, Desai Apurva, Karrison Theodore, Jiang Xuemin, Janisch Linda, Das Soma, Ramirez Jacqueline, Poonkuzhali Balasubramanian, Schuetz Erin, Fackenthal Donna Lee, Chen Peixian, Armstrong Deborah K, Brahmer Julie R, Fleming Gini F, Vokes Everett E, Carducci Michael A, Ratain Mark |
| CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis 2009 Jul 30 (7): 1161-9. Timofeeva Maria N, Kropp Silke, Sauter Wiebke, Beckmann Lars, Rosenberger Albert, Illig Thomas, Jäger Birgit, Mittelstrass Kirstin, Dienemann Hendrik, , Bartsch Helmut, Bickeböller Heike, Chang-Claude Jenny C, Risch Angela, Wichmann Heinz-Eri |
| Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jul 27 (21): 3540-6. Gandara David R, Kawaguchi Tomoya, Crowley John, Moon James, Furuse Kiyoyuki, Kawahara Masaaki, Teramukai Satoshi, Ohe Yuichiro, Kubota Kaoru, Williamson Stephen K, Gautschi Oliver, Lenz Heinz Josef, McLeod Howard L, Lara Primo N, Coltman Charles Arthur, Fukuoka Masahiro, Saijo Nagahiro, Fukushima Masanori, Mack Philip |
| Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of non-small cell lung cancer. Experimental and therapeutic medicine 2012 Aug 4 (2): 317-322. Kim Kyu-Sik, Oh In-Jae, Ban Hee-Jung, Cho Hyun-Ju, Kwon Yong-Soo, Kim Yu-Il, Lim Sung-Chul, Na Kook-Joo, Song Sang-Yun, Choi Song, Choi Yoo-Duk, Kim Young-Ch |
| Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clinical pharmacokinetics 2013 Jul 52 (7): 593-609. Fukudo Masahide, Ikemi Yasuaki, Togashi Yosuke, Masago Katsuhiro, Kim Young Hak, Mio Tadashi, Terada Tomohiro, Teramukai Satoshi, Mishima Michiaki, Inui Ken-Ichi, Katsura Toshi |
| Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014 Feb 35 (2): 1671-8. Islam Mohammad Safiqul, Mostofa A G M, Ahmed Maizbha Uddin, Bin Sayeed Muhammad Shahdaat, Hassan Md Rajib, Hasnat Ab |
| Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer 2015 Jul 16 (4): 274-81. Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masato |
| Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2016 Sep 99 1-3. Zenke Yoshitaka, Umemura Shigeki, Sugiyama Eri, Kirita Keisuke, Matsumoto Shingo, Yoh Kiyotaka, Niho Seiji, Ohmatsu Hironobu, Goto Koic |
| Effects of CYP3A5 genetic polymorphism and smoking on the prognosis of non-small-cell lung cancer. OncoTargets and therapy 2016 9 1461-9. Jiang Li-Peng, Zhu Zhi-Tu, He Chun-Y |
| Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2016 Mar 93 69-76. Hirose Takashi, Fujita Ken-Ichi, Kusumoto Sojiro, Oki Yasunari, Murata Yasunori, Sugiyama Tomohide, Ishida Hiroo, Shirai Takao, Nakashima Masanao, Yamaoka Toshimitsu, Okuda Kentaro, Ohmori Tohru, Sasaki Yasutsu |
| Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters. Biological & pharmaceutical bulletin 2018 41 (1): 47-56. Endo-Tsukude Chihiro, Sasaki Ji-Ichiro, Saeki Sho, Iwamoto Norihiro, Inaba Megumi, Ushijima Sunao, Kishi Hiroto, Fujii Shinji, Semba Hiroshi, Kashiwabara Kosuke, Tsubata Yukari, Hayashi Mitsuhiro, Kai Yuki, Saito Hideyuki, Isobe Takeshi, Kohrogi Hirotsugu, Hamada Akino |
| Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients. Frontiers in pharmacology 2020 11 664. Liao Dehua, Liu Zhigang, Zhang Yongchang, Liu Ni, Yao Dunwu, Cao Lizhi, Chen Yun, Fu Yilan, Yang Nong, Xiang Daxio |
| CYP4F2 and CYP3A5 gene polymorphisms and lung cancer in Chinese Han population. Clinical and experimental medicine 2020 Apr . He Ruiqing, Li Meng, Li Anqi, Dang Wenhui, Yang Tian, Li Jing, Zhang Ning, Jin Tianbo, Chen Mingw |
| Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. Investigational new drugs 2022 9 40 (6): 1254-1262. Yokota Hayato, Sato Kazuhiro, Sakamoto Sho, Okuda Yuji, Fukuda Natsuki, Asano Mariko, Takeda Masahide, Nakayama Katsutoshi, Miura Masato |
| Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities. Anti-cancer drugs 2022 Aug . Kwok Wang Chun, Lam David Chi Leung, Ip Mary Sau Man, Tam Terence Chi Chun, Ho James Chung M |
| Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer. Frontiers in pharmacology 2022 13 918219. Tan Tingfei, Han Gongwei, Cheng Ziwei, Jiang Jiemei, Zhang Li, Xia Zitong, Wang Xinmeng, Xia Qu |
| Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. BMC pulmonary medicine 2022 11 22 (1): 454. Nio Yuta, Ishida Hiroo, Matsumoto Natsumi, Kusumoto Sojiro, Kubota Yutaro, Tsunoda Takuya, Sasaki Yasutsuna, Fujita Ken-Ic |
| Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant. European journal of clinical pharmacology 2022 1 78 (4): 613-621. Hibino Hideyuki, Sakiyama Naomi, Makino Yoshinori, Makihara-Ando Reiko, Horinouchi Hidehito, Fujiwara Yutaka, Kanda Shintaro, Goto Yasushi, Yoshida Tatsuya, Okuma Yusuke, Shinno Yuki, Murakami Shuji, Hashimoto Hironobu, Akiyoshi Takeshi, Imaoka Ayuko, Ohe Yuichiro, Yamaguchi Masakazu, Ohtani Hisaka |
| Study on individualized analgesia guided by CYP3A4/5 polymorphisms in perioperative thoracoscopic surgery. American journal of translational research 2022 1 13 (12): 14211-14219. Wang Shengyan, Yao Yibing, Kong Min, Zhou Xuyan, Shen |
- Page last reviewed:Feb 1, 2024
- Content source: